By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
News
Snap to launch ‘Specs’ smart glasses to revive challenge to Meta and Apple
2 hours ago
News
US oil output set for first annual drop since pandemic
3 hours ago
News
Private capital group Blackstone plots $500bn expansion in Europe
4 hours ago
News
Meta plans to invest $15bn in Scale AI in bid to catch up to rivals
5 hours ago
Videos
Alcoa’s former CEO has a message for Trump
6 hours ago
Videos
What’s In The Big Beautiful Bill And Why Elon Musk Hates It
6 hours ago
News
Citi to boost provision for potential bad loans on US economic worries
6 hours ago
News
Netanyahu’s coalition teeters as ultra-Orthodox allies threaten to dissolve parliament
8 hours ago
News
US defence secretary defends deployment of Marines in LA
9 hours ago
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Pfizer borrows $31 billion in mega bond deal as debt issuance picks up ahead of debt-ceiling deadline
Investing

Pfizer borrows $31 billion in mega bond deal as debt issuance picks up ahead of debt-ceiling deadline

News Room
Last updated: 2023/05/17 at 4:13 AM
By News Room
Share
3 Min Read
SHARE

Pharmaceutical giant Pfizer secured $31 billion in financing on Tuesday, as companies pick up the pace of borrowing ahead of potential market turmoil tied to the U.S. debt-ceiling fight.

Pfizer
PFE,
-0.40%
borrowed the funds via an eight-tranche bond deal that will go toward its roughly $43 billion acquisition of Seagan, a biotech focused on creating therapies to treat cancer, according to public documents tied to the financing.

Pricing on the bonds, rated A1 by Moody’s Investors Service, narrowed about 20 basis points from initial expectations, with the $5 billion class of 10-year bonds clearing at a spread of 125 basis points above the risk-free Treasury rate
TMUBMUSD10Y,
3.532%,
or a yield of about 4.7%, according to a person with direct knowledge of the dealings.

Bankers initially pitched the bonds to investors at a range of Treasurys plus 145 basis points, according to CreditSights. Lower spreads mean investors receive less compensation.

The bond deal ranks as the fourth-largest on record for the U.S. investment-grade corporate bond market, according to data from Informa Global Markets.

Analysts at BofA Global this week noted an uptick in U.S. investment-grade corporate bond supply, with issuance in May (see chart) already exceeding the $69 billion priced in April.

While the chart doesn’t include Tuesday’s mega financing for Pfizer, it does show the dramatic drop in issuance volume in March from a year ago, when the Federal Reserve began to quickly raise rates from nearly zero. It also shows May issuance increased from a month before.

“The acceleration this week could be, at least in part, due to the upcoming U.S. debt-limit X-date in early June,” a team of BofA Global researchers, led by Yuri Seliger, wrote in a recent client note.

Pfizer didn’t immediately respond to a request for comment. Its shares closed 0.4% lower Tuesday.

Treasury Secretary Janet Yellen in early May said the U.S. could be unable to pay all of its bills by June 1, a warning she repeated earlier this week.

After a second round of debt-ceiling talks between President Joe Biden and congressional leaders Tuesday, House Speaker Kevin McCarthy said disagreements remain but that a deal might be possible by the end of the week.

See: McCarthy says second debt-ceiling meeting was ‘a little more productive,’ while Biden says he’s optimistic

Stocks closed lower on Tuesday, with the Dow Jones Industrial Average
DJIA,
-1.01%
closing 336 points, or 1%, lower, while the S&P 500 index
SPX,
-0.64%
fell 0.6 and the Nasdaq Composite Index
COMP,
-0.18%
shed 0.2%.

Read the full article here

News Room May 17, 2023 May 17, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Snap to launch ‘Specs’ smart glasses to revive challenge to Meta and Apple

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

US oil output set for first annual drop since pandemic

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Private capital group Blackstone plots $500bn expansion in Europe

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Meta plans to invest $15bn in Scale AI in bid to catch up to rivals

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Alcoa’s former CEO has a message for Trump

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?